[go: up one dir, main page]

CO2018001339A2 - Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados - Google Patents

Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados

Info

Publication number
CO2018001339A2
CO2018001339A2 CONC2018/0001339A CO2018001339A CO2018001339A2 CO 2018001339 A2 CO2018001339 A2 CO 2018001339A2 CO 2018001339 A CO2018001339 A CO 2018001339A CO 2018001339 A2 CO2018001339 A2 CO 2018001339A2
Authority
CO
Colombia
Prior art keywords
fadv
vectors
associated methods
avian adenovirus
vector system
Prior art date
Application number
CONC2018/0001339A
Other languages
English (en)
Inventor
Yanlong Pei
James Ackford
Juan Carlos Corredor
Peter J Krell
Éva Nagy
Original Assignee
Univ Guelph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Guelph filed Critical Univ Guelph
Publication of CO2018001339A2 publication Critical patent/CO2018001339A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen vectores virales recombinantes obtenidos de adenovirus aviar 9 (FAdV-9) y métodos asociados. Los vectores FAdV-9 recombinantes pueden incluir una o más supresiones en el extremo izquierdo y/o extremo derecho del genoma de FAdV-9. Opcionalmente, los vectores incluyen una o más secuencias de nucleótidos exógenas, tales como secuencias que codifican un polipéptido de interés. Los vectores FAdV-9 recombinantes se pueden usar como un vector de suministro doble. También se describe el uso de los vectores para generar una respuesta inmunogénica en un sujeto y/o para prevenir una enfermedad.
CONC2018/0001339A 2015-07-10 2018-02-09 Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados CO2018001339A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562190913P 2015-07-10 2015-07-10
PCT/CA2016/050811 WO2017008154A1 (en) 2015-07-10 2016-07-11 Fowl adenovirus 9 (fadv-9) vector system and associated methods

Publications (1)

Publication Number Publication Date
CO2018001339A2 true CO2018001339A2 (es) 2018-04-30

Family

ID=57756612

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0001339A CO2018001339A2 (es) 2015-07-10 2018-02-09 Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados

Country Status (14)

Country Link
US (2) US20190153470A1 (es)
EP (1) EP3320100B1 (es)
CA (1) CA2991925A1 (es)
CO (1) CO2018001339A2 (es)
EA (1) EA201890274A1 (es)
ES (1) ES2996307T3 (es)
HU (1) HUE069664T2 (es)
IL (1) IL256801B (es)
MX (1) MX2018000353A (es)
PE (1) PE20181087A1 (es)
PL (1) PL3320100T3 (es)
RS (1) RS66242B1 (es)
WO (1) WO2017008154A1 (es)
ZA (1) ZA201800705B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020730A1 (es) * 2014-08-08 2016-02-11 Laboratorio Avi-Mex, S.A. De C.V. Vacuna en vector recombinante de adenovirus aviar serotipo 9
WO2019143803A1 (en) * 2018-01-17 2019-07-25 Adrenas Therapeutics, Inc. Adeno-associated virus gene therapy for 21-hydroxylase deficiency
MX2022012060A (es) * 2020-03-29 2023-02-14 Greffex Inc Vectores adenovirales de ave deficientes en la replicacion, sus dise?os y usos.
CN112094824B (zh) * 2020-08-19 2021-04-20 湖北省农业科学院畜牧兽医研究所 表达禽腺病毒4型截短Fiber2蛋白的重组新城疫病毒耐热疫苗株及其制备方法与应用
CN113584231B (zh) * 2021-09-10 2024-04-19 广西壮族自治区兽医研究所 鉴定i群禽腺病毒血清8型的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6296852B1 (en) * 1993-04-14 2001-10-02 Commonwealth Scientific And Industrial Research Organisation Recombinant avian adenovirus vector
DE19615803A1 (de) * 1996-04-20 1997-10-23 Boehringer Ingelheim Int CELO-Virus
US6841158B1 (en) * 1998-09-22 2005-01-11 Boehringer Ingelheim International Gmbh Recombinant celo virus and celo virus DNA
BRPI0822947B1 (pt) * 2008-11-19 2018-09-18 Laboratorio Avi Mex S A De Cv vacina recombinante.

Also Published As

Publication number Publication date
WO2017008154A1 (en) 2017-01-19
IL256801B (en) 2021-10-31
US20210317476A1 (en) 2021-10-14
EP3320100C0 (en) 2024-08-28
MX2018000353A (es) 2018-03-14
BR112018000194A2 (pt) 2018-09-11
IL256801A (en) 2018-03-29
RS66242B1 (sr) 2024-12-31
EP3320100B1 (en) 2024-08-28
EP3320100A1 (en) 2018-05-16
PE20181087A1 (es) 2018-07-09
EA201890274A1 (ru) 2018-08-31
PL3320100T3 (pl) 2025-01-20
EP3320100A4 (en) 2018-12-26
HUE069664T2 (hu) 2025-04-28
ZA201800705B (en) 2018-12-19
US20190153470A1 (en) 2019-05-23
CA2991925A1 (en) 2017-01-19
ES2996307T3 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
CO2018001339A2 (es) Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados
MX2016011686A (es) Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
MX391208B (es) Vectores del virus adenoasociado de b-sarcoglicano y microarn-29 y el uso de los mismos en la distrofia muscular.
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
MX2022015080A (es) Variantes de hsd17b13 y usos de las mismas.
CO2019006541A2 (es) Administración viral de neoantígenos
DOP2024000040A (es) Vacunas para vhb y métodos de tratamiento de vhb
CO2017010831A2 (es) Adenovirus oncolítico que codifica una proteína b7
MX2017005958A (es) Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas.
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
AR105470A1 (es) Métodos para inducir una respuesta inmune
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CL2016000502A1 (es) Vectores mejorados del factor viii del virus adeno-asociado de menos de 5,0 kb de longitud, que producen un polipéptido del factor viii funcionalmente activo para el tratamiento de la hemofilia a.
MX2018000307A (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
MX2018000845A (es) Vector vírico orf recombinante.
UY37408A (es) Vacuna de vectores contra el virus de la gripe “a” porcina
MX2018004542A (es) Neoepítopos virales y sus usos.
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
CO2019012289A2 (es) Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar
CO2018007442A2 (es) Vacunas contra el cáncer
EA201990719A1 (ru) Новые промоторы
MX2021008832A (es) Composiciones y metodos para la administracion de polipeptidos cftr.